New Delhi : Pharma major Eli Lilly and Company announced launch Humalog 200U/mL KwikPen used in the treatment of diabetes in the Indian market.
Humalog 200U/mL KwikPen is a pre-filled pen containing a concentrated formulation of Lilly’s rapid-acting insulin Humalog.
“Humalog 200U/mL KwikPen contains concentrated 200U/mL rapid acting insulin and delivers the same units of insulin in half the volume as 100U/mL meal-time insulin pens. It holds twice as many insulin units, hence it lasts longer and allows fewer pen changes every month,” the company said in a statement.
“Patients may require dosage increase over time for better glycemic control. Humalog 200U/mL KwikPen provides physicians a new prescription option for their patients,” Eli Lilly and Company (India) MD Edgard Olaizola said.
Medical Director Tarun Puri said: “Humalog 200U/mL KwikPen is bio equivalent to Humalog 100U/mL. Therefore, similar efficacy and safety as Humalog 100U/mL.